Show simple item record

dc.contributor.authorCol, Nananda F.
dc.contributor.authorGoldberg, Robert J.
dc.contributor.authorOrr, Richard K.
dc.contributor.authorErban, John K.
dc.contributor.authorFortin, Jennifer M.
dc.contributor.authorChlebowski, Rowan T.
dc.date2022-08-11T08:10:38.000
dc.date.accessioned2022-08-23T17:15:22Z
dc.date.available2022-08-23T17:15:22Z
dc.date.issued2002-10-09
dc.date.submitted2010-05-27
dc.identifier.citationMed Decis Making. 2002 Sep-Oct;22(5):386-93.
dc.identifier.issn0272-989X (Linking)
dc.identifier.pmid12365480
dc.identifier.urihttp://hdl.handle.net/20.500.14038/47152
dc.description.abstractThe authors estimate tamoxifen's impact on life expectancy among healthy women. A Markov model compared the effects of 5 years of tamoxifen on survival among 50-year-old postmenopausal women. Scenarios were explored using alternative assumptions with regard to tamoxifen's long-term effects on breast and endometrial cancer. Postmenopausal women without a uterus had substantial life expectancy gains from tamoxifen (1 to 4 months), whereas women with a uterus had such gains only if they were at a very high breast cancer risk. If tamoxifen's impact on endometrial cancer persists after treatment is discontinued, women at high risk for endometrial cancer have life expectancy losses from tamoxifen unless they are at a very high risk for breast cancer. The authors conclude that tamoxifen use among postmenopausal women is associated with substantial life expectancy gains. However, this benefit is modulated in women at increased endometrial cancer risk and depends on assumptions concerning tamoxifen's lingering effects on breast and endometrial cancer.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=12365480&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1177/027298902236942
dc.subjectAnticarcinogenic Agents
dc.subjectBreast Neoplasms
dc.subjectCohort Studies
dc.subject*Decision Support Techniques
dc.subjectEndometrial Neoplasms
dc.subjectFemale
dc.subjectHumans
dc.subjectHysterectomy
dc.subject*Life Expectancy
dc.subject*Markov Chains
dc.subjectMiddle Aged
dc.subjectPatient Selection
dc.subject*Postmenopause
dc.subjectPredictive Value of Tests
dc.subjectRisk Assessment
dc.subjectRisk Factors
dc.subject*Survival Analysis
dc.subjectTamoxifen
dc.subjectThromboembolism
dc.subjectTime Factors
dc.subjectBioinformatics
dc.subjectBiostatistics
dc.subjectEpidemiology
dc.subjectHealth Services Research
dc.titleSurvival impact of tamoxifen use for breast cancer risk reduction: projections from a patient-specific Markov model
dc.typeJournal Article
dc.source.journaltitleMedical decision making : an international journal of the Society for Medical Decision Making
dc.source.volume22
dc.source.issue5
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/qhs_pp/301
dc.identifier.contextkey1333054
html.description.abstract<p>The authors estimate tamoxifen's impact on life expectancy among healthy women. A Markov model compared the effects of 5 years of tamoxifen on survival among 50-year-old postmenopausal women. Scenarios were explored using alternative assumptions with regard to tamoxifen's long-term effects on breast and endometrial cancer. Postmenopausal women without a uterus had substantial life expectancy gains from tamoxifen (1 to 4 months), whereas women with a uterus had such gains only if they were at a very high breast cancer risk. If tamoxifen's impact on endometrial cancer persists after treatment is discontinued, women at high risk for endometrial cancer have life expectancy losses from tamoxifen unless they are at a very high risk for breast cancer. The authors conclude that tamoxifen use among postmenopausal women is associated with substantial life expectancy gains. However, this benefit is modulated in women at increased endometrial cancer risk and depends on assumptions concerning tamoxifen's lingering effects on breast and endometrial cancer.</p>
dc.identifier.submissionpathqhs_pp/301
dc.contributor.departmentDepartment of Medicine, Division of Cardiovascular Medicine
dc.source.pages386-93


This item appears in the following Collection(s)

Show simple item record